Gastrointestinal

News on in vitro diagnostics for gastrointestinal disease.

The tests detect Campylobacter jejuni and Campylobacter coli and improve upon currently available immunoassays and culture tests, the firm said.

Researchers at Cincinnati Children's Hospital have identified markers for earlier detection of the condition, for which patient outcomes hinge on rapid action.

The company said it will use the proceeds to accelerate development of its gastrointestinal platform, including diagnostics and therapeutics for the GI tract.

The firm said that a number of hospitals and labs are expected to evaluate the panel, presenting it with about a $2.0 million annual revenue opportunity.  

The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.